HRMY Harmony Pharma: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Risks for Harmony Biosciences (HRMY) are tied to the dependence on a single drug and patent expiration dates. The rolling annual change in net income per share demonstrates the growth trajectory, where the -4.80 level captures the current state. Operations in the US market provide stability, despite logistics from Asia. Wakix supports profitability, although new pipeline drivers are only beginning to emerge.
Harmony Biosciences - פילוחים אנליטיים ומדדי מפתח (HRMY)

To assess the fundamental stability of Harmony Biosciences (HRMY), investors must analyze the growth rates of net income per share on a rolling year basis. Analyzing the EPS TTM YoY trend allows for the tracking of continuous annual EPS growth, which confirms the effectiveness of Harmony Biosciences (HRMY) dominance in the sleep medication segment and its ability to generate profit despite the imminent arrival of new competitors.